Peer reviewed
Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
International Journal of Neuropsychopharmacology (2020). Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
International Journal of NeuropsychopharmacologyAccessed Aug 5, 2026
Registry record
Source metadata
- Publisher
- International Journal of Neuropsychopharmacology
- Source type
- Peer reviewed
- Registry ID
pubmed-cerebrolysin-donepezil-vegf-2020- DOI
- 10.1093/ijnp/pyaa046
- PMID
- 32640027
Source usage
Not yet linked from a public content page
This record may be retained for an upcoming review or for internal source normalization.
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.